MALDI Biotyper® (MBT): Launch of proprietary MBT Easy T® Kit for consistent sample transfer to MALDI target plates
MALDI Biotyper®: Expansion of reference libraries to more than 5,300 species, spanning bacteria, yeasts, filamentous fungi, and mycobacteria
MALDI Biotyper®: Early KOL access to a novel cloud‑based identification solution, enabling identification against several specialist, expert‑curated libraries
MALDI Biotyper®: Ongoing broad, multi‑year clinical and translational study programs advancing automation, potential future claims, and next‑generation analytics, including:
U.S. clinical studies intended to support upcoming identification claims for mycobacteria and filamentous fungi, with FDA submission targeted for 2026
Ongoing clinical evaluation of MBT FAST, a rapid phenotypic antimicrobial susceptibility testing approach, aiming to enable IVDR-compliant same‑day results from positive blood cultures and agar colonies for Enterobacteriaceae
Exploratory, data‑driven research studies presented at ESCMID, including AI‑based antibiotic resistance prediction for Staphylococcus aureus, derived from large MALDI Biotyper spectral datasets
IR Biotyper®: Enhanced outbreak detection with IR Tracker for surveillance of hospital‑acquired infections (HAIs) and new classifiers for Salmonella Typhi, STEC, and Shigella sp. detection
MBioSEQ™ Ridom Typer: New software version, including TB‑Profiler antimicrobial resistance (AMR) determination, and GAMBIT bacterial species identification supporting MALDI / IR Biotyper®-triggered WGS reflex testing workflows, with result application performed under laboratory responsibility
Introduction of Molzym as a part of Bruker Microbiology and Infection Diagnostics
Login to comment